During the course of chronic hepatitis B virus. Long-Term Outcome After Spontaneous HBeAg Seroconversion in Patients With Chronic Hepatitis B
|
|
- Mervyn Warren
- 5 years ago
- Views:
Transcription
1 Long-Term Outcome After Spontaneous HBeAg Seroconversion in Patients With Chronic Hepatitis B Yao-Shih Hsu, 1 Rong-Nan Chien, 1 Chau-Ting Yeh, 1 I-Shyan Sheen, 1 Hung-Yi Chiou, 2 Chia-Ming Chu, 1 and Yun-Fan Liaw, 1 During the course of chronic hepatitis B virus (HBV) infection, hepatitis B e antigen (HBeAg) seroconversion to its antibody (anti-hbe) often coincides with normalization of liver biochemical test and clinical remission, but data regarding long-term outcome after spontaneous seroconversion are still scarce. Excluding patients with other virus(es) concurrent infection, 283 patients with chronic HBV infection were followed up for at least 1 year after spontaneous HBeAg seroconversion to anti-hbe. Follow-up studies included clinical, biochemical, and virologic evaluation and hepatocellular carcinoma (HCC) screening with ultrasonography and -fetoprotein assay. During a median follow-up period of 8.6 years (range, 1 to 18.4 years) after HBeAg seroconversion in 283 patients, 189 (66.8%) showed sustained remission, whereas the remaining 94 (33.2%) experienced alanine aminotransferase (ALT) elevation over twice the upper limit of normal: 12 (4.2%) associated with HBeAg reversion, 68 (24%) with detectable serum HBV DNA but HBeAg negative, and 14 (4.9%) of undetermined causes. Of the 269 patients without evidence of cirrhosis at the time of HBeAg seroconversion, 21 (7.8%) developed cirrhosis with a cumulative incidence and relative risk significantly higher in patients developing active hepatitis than in patients with sustained remission (P <.05). HCC developed in 6 (2.2%) of the 283 patients, also with a significantly higher cumulative incidence in patients developing active hepatitis after HBeAg seroconversion (P <.005). In conclusion, the results suggest that spontaneous HBeAg seroconversion confers favorable long-term outcomes. However, active hepatitis still may develop and lead to cirrhosis and HCC. (HEPATOLOGY 2002;35: ) During the course of chronic hepatitis B virus (HBV) infection, presence of hepatitis B e antigen (HBeAg) often is associated with active and usually continuing liver disease, whereas HBeAg seroconversion to its antibody (anti-hbe) often coincides with loss of serum HBV DNA, normalization of liver biochemical test, clinical remission and subsidence of hepatic Abbreviations: HBV, hepatitis B virus; HBeAg, hepatitis B e antigen; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HDV, hepatitis D virus; ALT, alanine aminotransferase; HBsAg, hepatitis B surface antigen. From the 1 Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University; and the 2 School of Public Health, Taipei Medical University, Taipei, Taiwan. Received August 2, 2001; accepted March 16, Y.-S.H. is currently affiliated with the Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan. Supported by a grant from the Chang Gung Medical Research Fund (CMRP800). Address reprint requests to: Yun-Fan Liaw, M.D., Liver Research Unit, Chang Gung Memorial Hospital, 199, Tung Hwa North Rd, Taipei, Taiwan liveryfl@so-net.net.tw; fax: (886) Copyright 2002 by the American Association for the Study of Liver Diseases /02/ $35.00/0 doi: /jhep inflammatory activity, 1-4 and may even be followed by spontaneous HBV surface antigen (HBsAg) seroclearance. 5 Several studies have shown that the long-term outcome of the patients after interferon-related HBeAg seroconversion is favorable However, few studies have addressed the issue of long-term outcome after spontaneous HBeAg seroconversion. 11 Given the fact that most patients with liver cirrhosis and hepatocellular carcinoma (HCC) are seropositive for anti-hbe, it has even been suggested that the risk of HCC might increase when HBV infection became quiescent. 12 Therefore, we conducted this study to elucidate the long-term outcome after spontaneous HBeAg seroconversion in a large series of patients. Patients and Methods Patients. The long-term follow-up study of our patients with chronic hepatitis B, as described previously, 5,10,13 has continued. By the end of 1998, a total of 1,345 HBeAg seropositive patients were confirmed to have chronic hepatitis B by liver biopsy at entry to our 1522
2 HEPATOLOGY, Vol. 35, No. 6, 2002 HSU ET AL follow-up program. Excluding 361 patients who received anti-hbv therapy (interferon, thmosin- 1 or lamivudine) and others with concurrent hepatitis C virus (HCV), hepatitis delta virus (HDV) infection, or other liver diseases (cirrhosis, alcoholic, autoimmune), 283 patients had well-documented spontaneous HBeAg seroconversion to anti-hbe 1 to 203 (median, 32) months after entry and were followed-up for more than 1 year after HBeAg seroconversion. They formed the basis of this study. Methods. After HBeAg seroconversion, the patients were followed up every 6 months or more frequently when clinically indicated, such as for alanine aminotransferase (ALT) elevation. Follow-up studies included clinical, biochemical, and virologic aspects as well as HCC screening using ultrasonography and alfa-fetoprotein. Liver biopsy was routinely advised when it was indicated, such as ALT elevation and when liver cirrhosis or HCC was suspected. A total of 74 biopsies were performed in 61 patients who gave written, informed consent. The biochemical tests were measured using routine automated techniques and carried out in the clinical pathology laboratories of Chang Gung Memorial Hospital. HBsAg, antibody to HDV, HBeAg, and anti-hbe were all assayed using commercially available radioimmunoassay kits (Ausria II, and anti-delta, Abbott Laboratories, North Chicago, IL; HBeAg/anti-HBe test, Diasorin, Saluggia, Italy). Serum samples also were assayed for anti-hcv with a second- or third-generation enzyme immunoassay kit (Abbott Laboratories). Stored serum specimens of the patients having ALT elevation during follow-up were assayed for HBV DNA retrospectively with a signal amplification hybridization assay (Digene HBV test, Hybrid Capture II, Digene Corp., MD). The detection sensitivity of this assay is 0.5 pg/ml. The first available serum specimens during ALT elevation in 47 patients with HBeAg negative hepatitis were further processed by an amplification-created restriction site method 14 to determine whether there was a stop codon in the precore region. Real-time ultrasonography (Aloka SSD, 620; Aloka Co, Ltd, Tokyo, Japan) was performed every 6 months, or every 3 months if the patients had developed cirrhosis. The development of cirrhosis was diagnosed by histology or imaging features suggestive of cirrhosis supplemented with the presence of esophageal varices, encephalopathy, or ascites. The diagnostic accuracy of ultrasonography for liver cirrhosis was at least 80%. 15,16 HCC was diagnosed by histology, cytology, or tumors found by ultrasonography or other diagnostic imaging methods with an elevated alfafetoprotein level greater than 400 ng/ml. 17 Patients that remained seropositive for anti-hbe with normal serum ALT through the course of follow-up were defined as sustained remission. Active hepatitis was defined as ALT elevation over 2 times the upper limit of normal on 2 occasions at least 2 weeks apart. Of the patients with active hepatitis, those who became seropositive for HBeAg again were classified as HBeAg reversion, those seropositive for HBV-DNA but seronegative for HBeAg were considered to have HBeAg negative hepatitis, whereas those seronegative for both HBeAg and HBV- DNA were classified as cause undetermined. Acute exacerbation was defined as an abrupt increase of ALT by 2-fold and to a level greater than 5 times the upper limit of normal, or to a level greater than 300 IU/L (n 40 IU/L), as described elsewhere. 13 Statistical Analysis. Statistical analysis was performed with the SAS software version 6.12 (SAS Institute Inc, Cary, NC). A logistic regression model was used to calculate univariate and multivariate odds ratios and their 95% CI. Statistical significance was tested by maximum likelihood function. Cumulative incidence rate was calculated with life table method. Kaplan-Meier survival analysis and log rank test were performed to test the cumulative incidence difference among these 3 groups (HBeAg reversion group, HBeAg-negative hepatitis group, and sustained remission group). Normal approximation method was used to examine the difference between the slope of cumulative incidence among various groups. Differences with a P value of less than.05 were considered significant. Results A total of 283 patients (231 male, 52 female) with spontaneous HBeAg seroconversion to anti-hbe during a median follow-up period of 32 months (range from 1 to 203 months) met our selection criteria and were included in this study. At the time of seroconversion, their median age was 32 years (16-58 years) and 14 patients (4.9%) had evidence of cirrhosis (9 confirmed histologically). After spontaneous HBeAg seroconversion, 74 follow-up liver biopsies were performed in 61 (22%) patients during a median period of 37 months (range, 1-87 months). Of these, 1 of 15 patients with sustained remission, 2 of 3 patients with HBeAg reversion, and 12 of 42 patients with HBeAg negative hepatitis showed liver cirrhosis (P.05). After seroconversion from HBeAg to anti-hbe, the majority of patients were asymptomatic with normal serum ALT. In a subsequent 9-year follow-up ( years; median, 8.6 years), 189 (66.8%) of the 283 patients showed sustained remission, whereas the remaining 94 (33.2%) experienced ALT elevation greater than twice the upper limit of normal or active hepatitis by definition. Of
3 1524 HSU ET AL. HEPATOLOGY, June 2002 these 94 patients with active hepatitis, 12 (12.8%) were seropositive for both HBeAg and HBV DNA (HBeAg reversion), and 68 (72.3%) were seropositive for HBV DNA but seronegative for HBeAg (HBeAg negative hepatitis). The remaining 14 (14.9%) were seronegative for both HBeAg and HBV DNA in all available serum specimens during hepatitis (cause undetermined). Seven (58.3%) patients with HBeAg reversion, 48 (70.6%) patients with HBeAg negative hepatitis, and 6 (42.9%) patients with undetermined cause showed persistent or intermittent ALT elevation, whereas the remaining patients showed transient ALT elevation. Stepwise logistic regression analysis on baseline variables including age, gender, ALT, HBV-DNA, and cirrhosis at the time of HBeAg seroconversion did not correlate to the development of new cirrhosis and HCC. Moreover, the logistic regression model showed no risk factors to predict developing acute exacerbation after HBeAg seroconversion. The pattern of ALT elevation did not correlate to the development of new cirrhosis in these 3 groups of patients. HBeAg reversion occurred 0.3 to 3.3 years (median, 1.1 years) after HBeAg seroconversion. Acute exacerbation was documented in 8 (67%) patients on or after HBeAg reversion with 1(13%) developing hepatic decompensation with prolongation of prothrombin time and marked jaundice. The HBe antigenemia was then maintained for a median period of 4 months (range, 3 to 45 months). Multivariate analysis showed that patients with more frequent acute exacerbation before HBeAg seroconversion or patients with liver cirrhosis at the time of HBeAg seroconversion had a significantly higher risk of developing HBeAg negative hepatitis (odds ratios of 10.37; 95% CI: and 3.56; 95% CI: , respectively), and patients with liver cirrhosis at the time of HBeAg seroconversion also were significantly associated with the risk of HBeAg reversion (odds ratio of 12.28; 95% CI: ). Of the 68 patients with HBeAg negative hepatitis, 16 (23.5%) were seropositive for HBV DNA at the time of seroconversion, whereas the remaining 52 patients became HBV DNA seropositive in the following years (Fig. 1).There were no differences in the ALT levels, HBV DNA levels, and incidence of new cirrhosis or HCC between those with early and late HBV viremia. Of the serum specimens from 47 patients with HBeAg negative hepatitis, 41 (87%) showed mixed or pure precore mutants. Development of Cirrhosis. Of the 269 patients without evidence of cirrhosis at the time of HBeAg seroconversion, 21 (7.8%) patients developed new cirrhosis (15 with histologic evidence, 6 diagnosed by clinical and imaging features) during follow-up with an estimated annual incidence of 0.9%. Breakdown data showed that 14 Fig. 1. The cumulative incidence of HBeAg-negative hepatitis over time after spontaneous HBeAg seroconversion. (23%) of the 62 patients with HBeAg-negative hepatitis, 5 (55%) of the 9 patients with HBeAg reversion, 1 (7%) of the 14 patients with active hepatitis of undetermined causes, and one (0.5%) of the 184 patients with sustained remission developed cirrhosis during the follow-up period (Table 1). The median time to development of cirrhosis was 204 and 127 months for the HBeAg negative hepatitis group and the HBeAg reversion group, respectively (Fig. 2).The cumulative incidence of cirrhosis development was highest in the HBeAg reversion group, followed by the HBeAg-negative hepatitis group, and then the sustained remission group. The differences were statistically significant among these 3 groups (P.0129) and between groups (all P.01) by log rank tests. Age/sexadjusted multivariate analysis showed that patients with HBeAg-negative hepatitis were significantly associated with new cirrhosis development, whereas age at the time of HBeAg seroconversion and male sex did not correlate with the risk of new cirrhosis development (Table 2). Development of HCC. HCC was detected 5.3 to 14.3 years after spontaneous HBeAg seroconversion in 6 patients (2.2%; 5 with histologic confirmation, 1 diagnosed by imaging features plus high alfa-fetoprotein level) with an estimated annual incidence of 0.2%. It occurred in 3 (1.6%) of the 189 patients with sustained remission and in 3 (4.4%) of the 68 patients with HBeAg-negative hepatitis. One (1.5%) patient in the latter group died of esophageal varices bleeding 1 year after diagnosis of HCC. The difference between the slope of cumulative incidence of HCC development was significantly higher in patients with HBeAg-negative hepatitis as compared with patients with sustained remission (P.005). However, age/sex-
4 HEPATOLOGY, Vol. 35, No. 6, 2002 HSU ET AL Table 1. Long-Term Outcomes After Spontaneous HBeAg Seroconversion Active Hepatitis Sustained Remission HBeAg ( ) HBV-DNA ( ) HBeAg ( ) HBV-DNA ( ) HBeAg ( ) HBV-DNA ( ) No. of patients Hepatitis onset age (median) Male (%) Liver biopsy Prior to HBeAg loss No Timing* 19 (1-185) 5 (1-79) 8 (1-175) 13.5 (1-123) After HBeAg loss No Timing* 12 (1-145) 26 (17-103) 44 (1-187) 7 Follow-up* 99 (24-218) 92 (14-130) 108 (12-221) 103 (34-196) Cirrhosis at entry 5 (2.6%) 3 (2.5%) 6 (8.8%) 0 New cirrhosis 1 (0.5%) 5 (55%) 14 (23%) 1 (7.1%) HCC 3 (1.6%) 0 3 (4.4%) 0 HBsAg seroclearance 9 (4.8%) 0 3 (4.4%) 0 NOTE. Entry: time of HBeAg seroconversion. *Data expressed as median (range) months. Data expressed as No. (%). adjusted multivariate analysis showed no difference in development of HCC among the 4 groups and the relative risk of HCC development was not significantly higher (odds ratio: 2.9; 95% CI: ) (Table 3). Loss of HBsAg. Nine (4.8%) of the 189 patients with sustained remission and 3 (4.4%) of the 68 patients with HBeAg-negative hepatitis underwent spontaneous HBsAg seroclearance 4.9 to 14.3 years after spontaneous HBeAg seroconversion (P.05) (Table 1). Discussion The results of the present study have shown that the majority of the patients had sustained remission whereas only 7.8% developed cirrhosis (0.9% per year) and 2.2% developed HCC (0.2% per year) during a median follow-up period of 9 years after spontaneous HBeAg seroconversion. These long-term results are far better than those of HBeAg-positive patients 16,17 and have confirmed the short-term observation that spontaneous HBeAg seroconversion confers favorable outcome (1 5). Given the fact that follow-up liver biopsies were not performed in all patients, it is possible that progression to compensated liver cirrhosis will be missed. However, the possible underestimation has been minimized by regular follow-up ultrasonography, which has a diagnostic accuracy of at least 80%. 15,16 Table 2. Relative Risk of Cirrhosis Development Variable Group Number at Entry New Cirrhosis Odds Ratio 95% CI P Fig. 2. The cumulative incidence of cirrhosis development after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. The incidence of cirrhosis development is significantly higher in patients with HBeAg reversion than in patients with HBeAg-negative hepatitis and also significantly higher in patients with HBeAg-negative hepatitis than patients with sustained remission (P.0129) by Kaplan-Meier survival analysis and log rank test. Age at entry (y) Sex Woman Man Sustained Remission Yes No HBeAg( ) HBV-DNA( )* HBeAg( ) HBV-DNA( )* HBeAg( ) HBV-DNA( )* *Compared with sustained remission.
5 1526 HSU ET AL. HEPATOLOGY, June 2002 Table 3. Relative Risk of HCC Development Variable Group Number at Entry Because many acute exacerbations of chronic HBV infection are subclinical or asymptomatic, 13 the single patient with sustained remission who developed cirrhosis after spontaneous HBeAg seroconversion might have experienced undetected subclinical episodes of hepatitis during the follow-up interval. Of note is that HCC developed in 3 (1.6%) patients with sustained remission, indicating the importance of HCC screening in asymptomatic HBsAg carriers, even in noncirrhotics. 17,18 Nevertheless, the relative risk of developing HCC and cirrhosis in the patients with sustained remission was significantly lower than that of the patients with hepatitis after spontaneous HBeAg seroconversion. Of note is that 33% of our patients experienced ALT elevation during long-term follow-up after spontaneous HBeAg seroconversion. This is consistent with the observation of Niederau et al. 9 that 2 (29%) of their untreated patients with spontaneous HBeAg clearance experienced continuing viral replication and inflammation during a mean follow-up period of 50 months. However, the HBeAg reversion rate after spontaneous HBeAg seroconversion in the present study was only 4.2%, which is lower than a rate over 10% after interferon-treated HBeAg seroconversion In contrast, HBeAg-negative hepatitis was rare after interferon-treated HBeAg seroconversion, 7-9 whereas it occurred in a much higher proportion (24%) of our patients with spontaneous HBeAg seroconversion. The reasons for these discrepancies are not clear and require further studies. Consistent with earlier observations, the present study also has shown that most reversions occurred within 1.5 years after HBeAg seroconversion and were often severe. 8,11,19 This may explain the high risk (5 in 9) of cirrhosis development in our patients with HBeAg reversion (Fig. 2), as was shown in our early study. 16 The most important finding in this study was that HBeAg-negative hepatitis accumulated over time after HBeAg seroconversion in 24% of the patients, and 87% of these patients had HBV strains with a point mutation at nucleotide 1896 in the precore region, or so-called HCC Odds Ratio 95% CI P Age at entry (y) Sex Woman Man Sustained remission Yes No HBeAg( ) HBV-DNA( )* *Compared with sustained remission. precore mutant. 20,21 In general, patients with chronic HBeAg-negative hepatitis usually run a progressively deteriorating course. 22 Our earlier study did show that HBV reactivation in anti-hbe positive patients increased the chance of cirrhosis development. 16 The present study also showed that 23% and 4.4% of our patients with HBeAgnegative hepatitis progressed to cirrhosis and HCC, respectively, with a significantly higher cumulative incidence of cirrhosis than patients with sustained remission (Fig. 2). Because data on HBV genotype and precore/core promotor variant were not available in the vast majority of the patients, the role of HBV genotypes in the clinical course of patients after HBeAg seroconversion is unknown. Similar to general HBV carriers in Taiwan, however, our patients with active hepatitis after HBeAg seroconversion also were genotype B predominant (85%, unpublished data). In conclusion, the present study suggests that spontaneous HBeAg seroconversion confers favorable long-term outcomes in the majority of patients. However, HBeAg reversion or HBeAg-negative hepatitis may develop in some patients who subsequently show an increased risk of cirrhosis or HCC, as compared with patients with sustained remission. Although the long-term outcomes after spontaneous HBeAg seroconversion are much better than HBeAg seropositive patients, surveillance of HCC is still required even in patients with sustained remission. Acknowledgment: The authors thank L.H. Lu and C.Y. Chen for their excellent technical assistance and S.C. Chen and S.C.Chu for their secretarial assistance. References 1. Realdi G, Alberti M, Rugge M, Bortolotti F, Rigoli AM, Tremolada F, Ruol A. Seroconversion from hepatitis B e antigen to anti-hbe in chronic hepatitis B virus infection. Gastroenterology 1980;79: Hoofnagle JH, Dusheiko GM, Seeff LB, Jones EA, Waggoner JG, Bales ZB. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis Ann Intern Med 1981;94: Liaw YF, Chu CM, Su IJ, Huang MJ, Lin DY, ChangChien CS. Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis. Gastroneterology 1983;84: Chu CM, Karayiannis P, Flower MJF, Monjardino J, Liaw YF, Thomas HC. Natural history of chronic hepatitis B virus infection in Taiwan: study of hepatitis B virus DNA in serum. HEPATOL- OGY 1985;5: Liaw YF, Sheen IS, Chen TJ, Chu CM, Pao CC. The incidence, determinants and significance of delayed clearance of serum hepatitis B surface antigen in chronic hepatitis B virus infection: A prospective study. HEPATOLOGY 1991;13: Lok ASF, Chung HT, Liu VW, Ma CCK. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology 1993;105:
6 HEPATOLOGY, Vol. 35, No. 6, 2002 HSU ET AL Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, Haussinger D. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996;334: Lau DT, Everhart J, Kleiner DE, Park Y, Vergalla J, Schmid P, Hoofnagle JH. Long-term follow-up of patients of chronic hepatitis B treated with interferon alfa. Gastroenterology 1997;113: Krogsgaard K. The long-term follow-up investigator group. The European study group on viral hepatitis (EUROHEP) executive team on antiviral treatment. The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis b. J Viral Hep 1998; Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. HEPATOLOGY 1999;29: Ruiz-Moreno M, Manuela O, Antonio M, Inmaculada C, Maria C, F Javier J, Horacio O, et al. Clinical and histological outcome after hepatitis B e antigen to antibody seroconversion in children with chronic hepatitis B. HEPATOLOGY 1999;29: Omata M. Treatment of chronic hepatitis B infection (Editorial). N Engl J Med 1998;339: Liaw YF, Tai DI, Chu CM, Pao CC, Chen TJ. Acute exacerbation in chronic type B hepatitis: comparison between HBeAg and antibody-positive patient. HEPATOLOGY 1987;7: Chu CM, Yeh CT, Chiu CT, Sheen IS, Liaw YF. Precore mutant of hepatitis B virus prevails in acute and chronic infection in an area in which hepatitis B is endemic. J Clin Microbiol 1996;34: Lin DY, Sheen IS, Chiu CT, Lin SM, Kuo YC, Liaw YF. Ultrasonographic changes of early liver cirrhosis in chronic hepatitis B: a longitudinal study. JCU 1993;21: Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. HEPATOLOGY 1988;8: Liaw YF, Tai DI, Chu CM, Lin DY, Sheen IS, Chen TJ, Pao CC. Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study. Gastroenterology 1986;90: Lin DY, Liaw YF. Optimal surveillance of hepatocellular carcinoma in patients with chronic viral hepatitis. J Gastroenterol Hepatol 2001;16: Davis GL, Hoofnagle JH, Waggoner JG. Spontaneous reactivation of chronic hepatitis B virus infection. Gastroenterology 1984; 86: Brunetto MR, Stemler M, Schodel F, Will H, Ottobrelli A, Rizzetto M, Verme G, et al. Identification of HBV variants which can not produce pre-core derived HBeAg and may be responsible for severe hepatitis. Ital J Gastroenterol 1989;21: Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, Mc- Garvey MJ, Makris A, Thomas HC. Mutation preventing formation of e antigen in patients with chronic HBV infection. Lancet 1989;2: Hadziyannis SJ. Hepatitis B e antigen negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment. Viral Hep Rev 1995;1:7-36.
Relative predictive factors for hepatocellular carcinoma after HBeAg seroconversion in HBV infection
PO Box 2345, Beijing 123, China World J Gastroenterol 25;11(43):6848-6852 www.wjgnet.com World Journal of Gastroenterology ISSN 17-9327 wjg@wjgnet.com E L S E V I E R 25 The WJG Press and Elsevier Inc.
More informationChronic hepatitis B virus (HBV) infection remains a major
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2010;8:541 545 Hepatitis B Virus DNA Level Predicts Hepatic Decompensation in Patients With Acute Exacerbation of Chronic Hepatitis B WEN JUEI JENG, I SHYAN SHEEN,
More informationNatural History of HBV Infection
Natural History of HBV Infection Joseph JY Sung MD PhD Institute of Digestive Disease Department of Medicine & Therapeutics Prince of Wales Hospital The Chinese University of Hong Kong HBV Infection 2
More informationHepatitis B virus (HBV) infection is a global
VIRAL HEPATITIS Serum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads Tai-Chung Tseng, 1,3,8 Chun-Jen Liu, 2,3 Hung-Chih Yang, 2,6 Tung-Hung
More informationJournal of Antimicrobial Chemotherapy Advance Access published April 25, 2013
Journal of Antimicrobial Chemotherapy Advance Access published April 25, 213 J Antimicrob Chemother doi:1.193/jac/dkt147 Virological response to entecavir reduces the risk of liver disease progression
More informationRole of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation
BRIEF REPORT Role of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation Man-Fung Yuen, 1 Erwin Sablon, 2 Danny Ka-Ho Wong, 1 He-Jun Yuan, 1 Benjamin Chun-Yu Wong, 1 Annie On-On Chan, 1 and
More informationChronic hepatitis B virus (HBV) infection affects
GASTROENTEROLOGY 2009;136:505 512 Predictive Factors for Early HBeAg Seroconversion in Acute Exacerbation of Patients With HBeAg-Positive Chronic Hepatitis B HYOUNG SU KIM,* HA JUNG KIM, WOON GEON SHIN,*
More informationNatural History of Chronic Hepatitis B
Natural History of Chronic Hepatitis B Anna SF Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor,
More informationSupplementary materials: Predictors of response to pegylated interferon in chronic hepatitis B: a
Supplementary materials: Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysis Yin-Chen Wang 1, Sien-Sing Yang 2*, Chien-Wei Su 1, Yuan-Jen Wang 3,
More informationCornerstones of Hepatitis B: Past, Present and Future
Cornerstones of Hepatitis B: Past, Present and Future Professor Man-Fung Yuen Queen Mary Hospital The University of Hong Kong Hong Kong 1 Outline Past Natural history studies Development of HBV-related
More informationWhat have we learned from HBV clinical cohorts?
PHC 2015: Hepatitis B What have we learned from HBV clinical cohorts? Jia-Horng Kao MD, Ph D Graduate Institute of Clinical Medicine, Hepatitis Research Center, Department of Internal Medicine, National
More informationLong-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease
Antiviral Therapy 12:1295 133 Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease Man-Fung Yuen, Wai-Kay
More informationDevelopment of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:889 893 Development of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen MYRON JOHN TONG,*, MICHAEL ONG NGUYEN, LORI TERESE TONG,
More informationLong-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance
Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance Gi-Ae Kim, Han Chu Lee *, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim,
More informationManagement of Chronic Hepatitis B in Asian Americans
Management of Chronic Hepatitis B in Asian Americans Myron J Tong; UCLA, CA Calvin Q. Pan; Mount Sinai, NY Hie-Won Hann; Thomas Jefferson, PA Kris V. Kowdley; Virginia Mason, WA Steven Huy B Han; UCLA,
More informationViral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg
Viral Hepatitis The Preventive Potential of Antiviral Therapy Thomas Berg Therapeutic and preventive strategies in patients with hepatitis virus infection Treatment of acute infection Treatment of chronic
More informationChronic infection with hepatitis B virus (HBV) is still a
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2012;10:527 534 Incidence and Determinants of Spontaneous Hepatitis B e Antigen and DNA in Patients With Chronic Hepatitis B HWAI I YANG,*,, HSIU LIAN HUNG, MEI
More informationEfficacy of Thymosin 1 in Patients With Chronic Hepatitis B: A Randomized, Controlled Trial
Efficacy of Thymosin 1 in Patients With Chronic Hepatitis B: A Randomized, Controlled Trial RONG-NAN CHIEN, 1 YUN-FAN LIAW, 1 TSE-CHING CHEN, 2 CHAU-TING YEH, 1 AND I.-SHYAN SHEEN 1 Thymosin 1 (T ) is
More informationCURRENT TREATMENT. Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia
CURRENT TREATMENT OF HBV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia CHRONIC HBV INFECTION DEMOGRAPHICS IN THE USA Estimated
More informationThe Impact of HBV Therapy on Fibrosis and Cirrhosis
The Impact of HBV Therapy on Fibrosis and Cirrhosis Jordan J. Feld, MD, MPH Associate Professor of Medicine University of Toronto Hepatologist Toronto Centre for Liver Disease Sandra Rotman Centre for
More informationViral hepatitis and Hepatocellular Carcinoma
Viral hepatitis and Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline
More informationChallenges in therapy of chronic hepatitis B
Journal of Hepatology 39 (2003) S230 S235 www.elsevier.com/locate/jhep Challenges in therapy of chronic hepatitis B Jay H. Hoofnagle* Division of Digestive Diseases and Nutrition, National Institute of
More informationC hronic hepatitis B (CHB) virus infection affects more
161 HEPATITIS Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications MF Yuen, HJ Yuan, D KH Wong, J CH Yuen, WM Wong, A OO Chan, B CY Wong, KC Lai, CL Lai... See end of article
More information29th Viral Hepatitis Prevention Board Meeting
29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis B José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HBV INFECTION
More informationSerum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads. Hepatology Feb 2013
Serum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads Hepatology Feb 2013 Hepatitis B Surface Antigen HBsAg is the glycosylated envelope
More informationOff-Therapy Durability of Response to Entecavir Therapy in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients
VIRAL HEPATITIS Off-Therapy Durability of Response to Entecavir Therapy in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients Wen-Juei Jeng, 1,2 I-Shyan Sheen, 1,2 Yi-Cheng Chen, 1,2 Chao-Wei
More informationHBV Core and Core-Related Antigen Quantitation in Chinese Patients with. Chronic Hepatitis B Genotype B and C Virus Infection
Title page HBV Core and Core-Related Antigen Quantitation in Chinese Patients with Chronic Hepatitis B Genotype B and C Virus Infection Short Title: Quantitation of HBc and HBcrAg in Chinese patients Akinori
More informationViral Hepatitis Diagnosis and Management
Viral Hepatitis Diagnosis and Management CLINICAL BACKGROUND Viral hepatitis is a relatively common disease (25 per 100,000 individuals in the United States) caused by a diverse group of hepatotropic agents
More informationChronic hepatitis B (CHB) infection is a large
AMERICAN ASSOCIATION FOR THE STUDY OFLIVERD I S E ASES HEPATOLOGY, VOL. 64, NO. 2, 2016 Serum Levels of Hepatitis B Surface Antigen and DNA Can Predict Inactive Carriers With Low Risk of Disease Progression
More informationTitle: Off therapy durability of response to Entecavir therapy in hepatitis B e
Title: Off therapy durability of response to Entecavir therapy in hepatitis B e antigen negative chronic hepatitis B patients Wen-Juei Jeng, MD 1,3, I-Shyan Sheen, MD 1-3, Yi-Cheng Chen, MD 1,3, Chao-Wei
More informationDoes Viral Cure Prevent HCC Development
Does Viral Cure Prevent HCC Development Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute of Digestive Disease Director, Center for Liver Health Assistant Dean,
More informationSATHEESH NAIR AND ROBERT P.PERRILLO
Serum Alanine Aminotransferase Flares During Interferon Treatment of Chronic Hepatitis B: Is Sustained Clearance of HBV DNA Dependent on Levels of Pretreatment Viremia? SATHEESH NAIR AND ROBERT P.PERRILLO
More informationSpontaneous hepatitis B e antigen (HBeAg) seroconversion
GASTROENTEROLOGY 2007;133:1466 1474 Pre-S Deletion and Complex Mutations of Hepatitis B Virus Related to Advanced Liver Disease in HBeAg-Negative Patients CHIEN HUNG CHEN,*, CHAO HUNG HUNG,* CHUAN MO LEE,*,,
More informationHealthy Liver Cirrhosis
Gioacchino Angarano Clinica delle Malattie Infettive Università degli Studi di Foggia Healthy Liver Cirrhosis Storia naturale dell epatite HCVcorrelata in assenza di terapia Paestum 13-15 Maggio 24 The
More informationConsensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition
Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition Anna S. Lok, MD, DSc Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research
More informationNatural history and prognostic factors for chronic hepatitis type B
294 Gut, 1991, 32, 294-298 LIVER, BILIARY, AND PANCREAS Istituto di Medicina Clinica, Clinica Medica 2, Universita di Padova, Italy G Fattovich L Brollo G Giustina F Noventa P Pontisso A Alberti A Ruol
More informationDNA 2 91% (185/203), 82% (75/91), 75% (47/63), 62% (26/42) 200,000, 20, ,999, 2,000-19,999, <2,000 ( P
Is There a Meaningful Serum Hepatitis B Virus DNA Cutoff Level for Therapeutic Decisions in Hepatitis B e Antigen Negative Chronic Hepatitis B Virus Infection? George V. Papatheodoridis, 1 Emanuel K. Manesis,
More informationHBV NATURAL HISTORY. Mitchell L. Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia
HBV NATURAL HISTORY AND MANAGMENT Mitchell L. Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia IVer Liver Institute of Virginia Education,
More informationPegasys Pegintron Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.47 Subsection: Anti-infective nts Original Policy Date: January 1, 2019 Subject: Pegasys Pegintron
More informationMedInform. HBV DNA loss in Bulgarian patients on NUC therapy. Speed related factors. (NUC related speed of HBV DNA loss in Bulgaria) Original Article
DOI: 10.18044/Medinform.201852.897 ISSUE 3, 2018 HBV DNA loss in Bulgarian patients on NUC therapy. Speed related factors. (NUC related speed of HBV DNA loss in Bulgaria) Donika Krasteva, Radosveta Tomova,
More informationManagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance
anagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance / 김강모 연수강좌 anagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance 김강모 울산대학교의과대학서울아산병원소화기내과
More informationGlobal Perspective on the Natural History of Chronic Hepatitis B: Role of Hepatitis B Virus Genotypes A to J
97 Global Perspective on the Natural History of Chronic Hepatitis B: Role of Hepatitis B Virus Genotypes A to J Chun-Jen Liu, MD, PhD 1,2,3 Jia-Horng Kao, MD, PhD 1,2,3,4 1 Graduate Institute of Clinical
More informationChronic hepatitis B (CHB) is the leading cause of
GASTROENTEROLOGY 2013;144:933 944 CLINICAL LIVER Accuracy of Risk Scores for Patients With Chronic Hepatitis B Receiving Entecavir Treatment GRACE LAI HUNG WONG, 1,2 HENRY LIK YUEN CHAN, 1,2 HOI YUN CHAN,
More informationMarch 29, :15 PM 1:15 PM San Diego, CA Convention Center Ballroom 20D
March 29, 2017 12:15 PM 1:15 PM San Diego, CA Convention Center Ballroom 20D Provided by #IM2017 This lunch symposium is not part of the official Internal Medicine Meeting 2017 Education Program. #IM2017
More informationChronic Hepatitis B: management update.
Chronic Hepatitis B: management update. E.O.Ogutu Department of clinical medicine & therapeutics, University of Nairobi. Physicians meeting,kisumu 2011. Background epidemiology Chronic hepatitis B (CHB)
More informationChoice of Oral Drug for Hepatitis B: Status Asokananda Konar
Choice of Oral Drug for Hepatitis B: Status 2011 Asokananda Konar Chronic hepatitis B (CHB) is a global public health challenge with an estimated 350 to 400 million people with chronic HBV infection, despite
More informationWho to Treat? Consider biopsy Treat. > 2 ULN Treat Treat Treat Treat CIRRHOTIC PATIENTS Compensated Treat HBV DNA detectable treat
Who to Treat? Parameter AASLD US Algorithm EASL APASL HBV DNA CRITERIA HBeAg+ >, IU/mL > 2, IU/mL > 2, IU/mL >, IU/mL HBeAg- > 2, IU/mL > 2, IU/mL > 2, IU/mL > 2, IU/mL ALT CRITERIA PNALT 1-2 ULN Monitor
More informationChronic hepatitis B is a major cause of end-stage
Predictors of HBeAg Loss After Lamivudine Treatment for Chronic Hepatitis B Robert P. Perrillo, 1 Ching-Lung Lai, 2 Yun-Fan Liaw, 3 Jules L. Dienstag, 4 Eugene R. Schiff, 5 Solko W. Schalm, 6 E. Jenny
More informationEstimation of Seroprevalence of Hepatitis B Virus and Hepatitis C Virus in Taiwan from a Large-scale Survey of Free Hepatitis Screening Participants
ORIGINAL ARTICLE Estimation of Seroprevalence of Hepatitis B Virus and Hepatitis C Virus in Taiwan from a Large-scale Survey of Free Hepatitis Screening Participants Chien-Hung Chen, 1 Pei-Ming Yang, 1
More informationESCMID Online Lecture Library. by author
Pro-Con: To stop or not to stop hepatitis B treatment? To Stop HBV Treatment Resat Ozaras, MD, Professor Istanbul University, Cerrahpasa Medical School, Infection Dept. HBV Therapy Nucleos(t)ide analogues
More informationHepatocellular Carcinoma: Can We Slow the Rising Incidence?
Hepatocellular Carcinoma: Can We Slow the Rising Incidence? K.Rajender Reddy M.D. Professor of Medicine Director of Hepatology Medical Director of Liver Transplantation University of Pennsylvania Outline
More informationHBV Diagnosis and Treatment
HBV Diagnosis and Treatment Anna S. F. Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor, MI, USA
More informationPathological Features and Prognosis in Chronic Hepatitis B Virus Carriers
The Journal of International Medical Research 2011; 39: 71 77 Pathological Features and Prognosis in Chronic Hepatitis B Virus Carriers ZH LU, W CHEN, ZC JU, H PEI, XJ YANG, XB GU AND LH HUANG Department
More informationPrediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term 2015
THAI J 16 GASTROENTEROL Treatment with Nucleos(t)ide Original Analogues Article Prediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term Treatment with Nucleos(t)ide Analogues Sombutsook
More informationViral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital
Viral Hepatitis Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis HAV HBV HCV HDV HEV Other viral: CMV, EBV, HSV Unknown Hepatitis A Hepatitis A Transmitted via the faecal-oral route
More informationHepatitis B Virus Genotype B Is Associated With Earlier HBeAg Seroconversion Compared With Hepatitis B Virus Genotype C
GASTROENTEROLOGY 2002;122:1756 1762 Hepatitis B Virus Genotype B Is Associated With Earlier HBeAg Seroconversion Compared With Hepatitis B Virus Genotype C CHI JEN CHU, MUNIRA HUSSAIN, and ANNA S. F. LOK
More informationRONG-NAN CHIEN, 1 YUN-FAN LIAW, 1 AND MARK ATKINS 2 FOR THE ASIAN HEPATITIS LAMIVUDINE TRIAL GROUP
Pretherapy Alanine Transaminase Level as a Determinant for Hepatitis B e Antigen Seroconversion During Lamivudine Therapy in Patients With Chronic Hepatitis B RONG-NAN CHIEN, 1 YUN-FAN LIAW, 1 AND MARK
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More informationClinical dilemmas in HBeAg-negative CHB
Clinical dilemmas in HBeAg-negative CHB George V. Papatheodoridis Professor in Medicine & Gastroenterology Medical School of National & Kapodistrian University of Athens Director of Academic Department
More informationIt is estimated that there are 1.25 million individuals
Treatment Recommendations for Chronic Hepatitis B: An Evaluation of Current Guidelines Based on a Natural History Study in the United States Myron John Tong, 1,2 Carlos Hsien, 2 Leeyen Hsu, 2 Hai-En Sun,
More informationChronic hepatitis B virus (HBV) infection is
HEPATOLOGY, VOL. 00, NO. 00, 2017 AMERICAN ASSOCIATION FOR THE STUDY OFLIVERD I S E ASES Incidence and Predictors of Hepatitis B Surface Antigen Seroclearance After Cessation of Nucleos(t)ide Analogue
More informationTreatment of chronic hepatitis B 2013 update
22 February 213 Treatment of chronic hepatitis B 213 update Pietro Lampertico 1st Gastroenterology Unit Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico Università di Milano EASL 212 Clinical
More informationManagement of Decompensated Chronic Hepatitis B
Management of Decompensated Chronic Hepatitis B Dr James YY Fung, FRACP, MD Department of Medicine The University of Hong Kong Liver Transplant Center Queen Mary Hospital State Key Laboratory for Liver
More informationARTICLE IN PRESS. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: An Update
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:xxx REVIEW A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: An Update EMMET B. KEEFFE,* DOUGLAS T. DIETERICH,
More informationIntron A Hepatitis B. Intron A (interferon alfa-2b) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.01 Subject: Intron A Hepatitis B Page: 1 of 7 Last Review Date: November 30, 2018 Intron A Hepatitis
More informationINTRODUCTION MATERIALS AND METHODS
J Korean Med Sci 2006; 21: 279-83 ISSN 1011-8934 Copyright The Korean Academy of Medical Sciences The Degrees of Hepatocyte Cytoplasmic Expression of Hepatitis B Core Antigen correlate with Histologic
More informationDiscontinuation of Nucleotide or Nucleoside Analogue therapy for Chronic Hepatitis B infection
Discontinuation of Nucleotide or Nucleoside Analogue therapy for Chronic Hepatitis B infection Dr Abid Suddle Institute of Liver Studies King s College Hospital Why consider discontinuation of NA therapy?
More informationClinical Management of Hepatitis B WAN-CHENG CHOW DEPARTMENT OF GASTROENTEROLOGY & HEPATOLOGY SINGAPORE GENERAL HOSPITAL
Clinical Management of Hepatitis B WAN-CHENG CHOW DEPARTMENT OF GASTROENTEROLOGY & HEPATOLOGY SINGAPORE GENERAL HOSPITAL The World Health Organisation recent initiatives on HBV infection Launching of the
More informationAlla ricerca del virus nascosto (quando il virus dell epatitie B si occulta )
Alla ricerca del virus nascosto (quando il virus dell epatitie B si occulta ) Giovanni Raimondo Epatologia Clinica e Biomolecolare Policlinico Universitario di Messina UI/ml pg/ml HBsAg HBeAg + anti-hbe
More informationChronic Hepatitis B Infection
Chronic Hepatitis B Infection Mohssen Nassiri Toosi, MD Imam Khomeinin Hospital Tehran University of Medical Sciences Chronic Hepatitis B Infection Virus : HBs Ag Positive Host Liver Health Chronic Hepatitis
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More informationHepatitis B (HBV) infection is a major worldwide
Clearance of Hepatitis B Surface Antigen and Risk of Hepatocellular Carcinoma in a Cohort Chronically Infected with Hepatitis B Virus Josephine Simonetti, 1 Lisa Bulkow, 2 Brian J. McMahon, 1,2 Chriss
More informationPegasys Hepatitis B. Pegasys (peginterferon alfa-2a) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.03.02 Subject: Pegasys Hepatitis B Page: 1 of 5 Last Review Date: September 18, 2015 Pegasys Hepatitis
More informationHBV in HIV Forgotten but not Gone
Activity Code FA376 HBV in HIV Forgotten but not Gone Richard K. Sterling, MD, MSc VCU Hepatology Professor of Medicine Chief, Section of Hepatology Virginia Commonwealth University Learning Objectives
More informationHepatitis B virus (HBV) infection is an important. Brief Communication
Brief Communication Hepatitis B Virus Infection in Children and Adolescents in a Hyperendemic Area: 15 Years after Mass Hepatitis B Vaccination Yen-Hsuan Ni, MD, PhD; Mei-Hwei Chang, MD; Li-Min Huang,
More informationDon t interfere My first choice is always nucs!
Don t interfere My first choice is always nucs! Robert G Gish MD Professor Consultant Stanford University Medical Director, Hepatitis B Foundation Singapore Viral Hepatitis Meeting 2014 1 Disclosures Dr
More informationYuen, MF; Sablon, E; Yuan, HJ; Hui, CK; Wong, DKH; Doutreloigne, J; Wong, BCY; Chan, AOO; Lai, CL
Title Author(s) Relationship between the development of precore and core promoter mutations and hepatitis B e antigen seroconversion in patients with chronic hepatitis B virus Yuen, MF; Sablon, E; Yuan,
More informationEndpoints of hepatitis B treatment
Journal of Viral Hepatitis, 2010, 17, 675 684 doi:10.1111/j.1365-2893.2010.01369.x REVIEW Endpoints of hepatitis B treatment W. Chotiyaputta and A. S. F. Lok Division of Gastroenterology, Department of
More informationIntron A (interferon alfa-2b) with ribavirin, (Copegus, Moderiba, Rebetol, Ribapak, Ribasphere, RibaTab, ribavirin tablets/capsules - all strengths)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Intron A Ribavirin Page: 1 of 5 Last Review Date: November 30, 2018 Intron A Ribavirin Description
More informationcoinfected patients predicts HBsAg clearance during long term exposure to tenofovir
Measurement of serum HBsAg in HIV/HBV coinfected patients predicts HBsAg clearance during long term exposure to tenofovir Zulema Plaza 1, Antonio Aguilera 2, Alvaro Mena 3, Luz Martín-Carbonero 1, Eugenia
More informationChronic hepatitis B is one of the leading causes of hepatocellular. Surrogate End Points and Long-Term Outcome in Patients With Chronic Hepatitis B
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:1113 1120 Surrogate End Points and Long-Term Outcome in Patients With Chronic Hepatitis B VINCENT WAI SUN WONG,*, GRACE LAI HUNG WONG,*, ANGEL MEI LING CHIM,*,
More informationLong-term tracking of hepatitis B viral load and the relationship with risk for hepatocellular carcinoma in men
Carcinogenesis vol.29 no.1 pp.106 112, 2008 doi:10.1093/carcin/bgm252 Advance Access publication November 13, 2007 Long-term tracking of hepatitis B viral load and the relationship with risk for hepatocellular
More informationART ICLEHepatitis B Virus Genotype and DNA Level and Hepatocellular Carcinoma: A Prospective Study in Men
ART ICLEHepatitis B Virus Genotype and DNA Level and Hepatocellular Carcinoma: A Prospective Study in Men Ming-Whei Yu, Shiou-Hwei Yeh, Pei-Jer Chen, Yun-Fan Liaw, Chih-Lin Lin, Chun-Jen Liu, Wei-Liang
More informationINDIAN JOURNAL OF MEDICAL SPECIALITIES 2010;1(2):97-105
INDIAN JOURNAL OF MEDICAL SPECIALITIES 2010;1(2):97-105 Review Article Approach to Chronic Hepatitis B Virus Infection Pankaj Tyagi, Pankaj Jain, Amit Mishra Abstract Hepatitis B virus (HBV) is one of
More informationPredicting response to peginterferon a-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B
699 HEPATITIS Predicting response to peginterferon a-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B F Bonino, P Marcellin, G K K Lau, S Hadziyannis, R Jin, T Piratvisuth, G
More informationPredicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B
Title Author(s) Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B Bonino, F; Marcellin, P; Lau, GKK; Hadziyannis, S; Jin, R; Piratvisuth,
More informationHepatitis Delta Virus and GBV-C Infection in Two Neighboring Hepatitis B Virus and Hepatitis C Virus Endemic Villages in Taiwan
Original Article 137 Hepatitis Delta Virus and GBV-C Infection in Two Neighboring Hepatitis B Virus and Hepatitis C Virus Endemic Villages in Taiwan Chang-Jung Chang 1, MD; Jui-Chin Chiang 1,2,6, MD; Sheng-Nan
More informationCLINICAL LIVER, PANCREAS, AND BILIARY TRACT. Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral Load
GASTROENTEROLOGY 2006;130:678 686 CLINICAL LIVER, PANCREAS, AND BILIARY TRACT Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral Load UCHENNA H. ILOEJE,* HWAI I YANG, JUN SU,*
More informationIntron A (interferon alfa-2b) with ribavirin, (Moderiba, Rebetol, Ribasphere, RibaTab, ribavirin tablets/capsules - all strengths)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.06 Subject: Intron A Ribavirin Page: 1 of 6 Last Review Date: March 18, 2016 Intron A Ribavirin Description
More informationChronic hepatitis B virus (HBV) infection can
Distinct Evolution and Predictive Value of Hepatitis B Virus Precore and Basal Core Promoter Mutations in Interferon-Induced Hepatitis B e Antigen Seroconversion Hung-Chih Yang, 1,2,3 Chi-Ling Chen, 2
More informationTHE FREQUENCY OF PRE-CORE GENE MUTATIONS IN CHRONIC HEPATITIS B INFECTION : A STUDY OF MALAYSIAN SUBJECTS
SOUTHEAST ASIAN J TROP MED PUBLIC HEALTH THE FREQUENCY OF PRE-CORE GENE MUTATIONS IN CHRONIC HEPATITIS B INFECTION : A STUDY OF MALAYSIAN SUBJECTS SF Yap 1, PW Wong 1, YC Chen 1 and M Rosmawati 2 1 Department
More informationRelation between serum quantitative HBsAg, ALT and HBV DNA levels in HBeAg negative chronic HBV infection
Relation between serum quantitative HBsAg, ALT and HBV DNA levels in HBeAg negative chronic HBV infection xxxxxxxxxxxxxxx Özgür Günal 1, Şener Barut 1, İlker Etikan 2, Fazilet Duygu 1, Umut Tuncel 3, Mustafa
More informationHepatitis B Update. Jorge L. Herrera, M.D. University of South Alabama Mobile, AL. Gastroenterology
Hepatitis B Update Jorge L. Herrera, M.D. University of South Alabama Mobile, AL Deciding Who to Treat Is hepatitis B a viral disease or a liver disease? Importance of HBV-DNA Levels in the Natural History
More informationPrecore and core promoter mutations of hepatitis B virus and hepatitis B e antigen-negative chronic hepatitis B in Korea
Journal of Hepatology 38 (2003) 98 103 www.elsevier.com/locate/jhep Precore and core promoter mutations of hepatitis B virus and hepatitis B e antigen-negative chronic hepatitis B in Korea Byung Chul Yoo
More informationNH2 N N N O N O O P O O O O O
N N NH 2 N N O O P O O O O O O James Watson and Francis Crick Double Helix 1953 Baruch Blumberg, MD, PhD 1925-2011 Australia Antigen 1965 Hepatitis B Virus (HBV) Hepadnaviridae member that primarily infects
More informationHBV Therapy in Special Populations: Liver Cirrhosis
HBV Therapy in Special Populations: Liver Cirrhosis Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More information2/12/2018. David M. Fettig, M.D. Birmingham Gastroenterology Associates. Outline basics of Hepatitis B. Phases of Chronic Hepatitis B
David M. Fettig, M.D. Birmingham Gastroenterology Associates Outline basics of Hepatitis B Phases of Chronic Hepatitis B Evaluation of Chronic Hepatitis B Treatment of Chronic Hepatitis B Special Populations
More informationAntiviral Therapy 11: Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan 2
Antiviral Therapy 11:985 994 A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre
More informationReceived 30 May 2004/Returned for modification 6 August 2004/Accepted 12 August 2004
JOURNAL OF CLINICAL MICROBIOLOGY, Nov. 2004, p. 5036 5040 Vol. 42, No. 11 0095-1137/04/$08.00 0 DOI: 10.1128/JCM.42.11.5036 5040.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved.
More information